NSGENE AS

Their core work

NSGENE AS is a Danish biotech SME working at the intersection of neuroscience and gene-based therapeutics, based in Ballerup — a hub for life sciences companies in the Copenhagen region. Their participation in two MSCA training networks focused on cell-based regenerative medicine and pain neuroscience indicates that they function as an industry host and applied research partner for early-career scientists. In this role they provide doctoral researchers with access to private-sector know-how, laboratory infrastructure, and commercial development context. Their dual presence in regenerative medicine and pain pathways suggests a niche around gene delivery or cell-based approaches for neurological and musculoskeletal conditions.

What they specialise in

How they've shifted over time

Both projects launched within one year of each other (2016–2017) and no keyword data is available, making it impossible to trace a clear technical shift. What is notable is that NSGENE engaged simultaneously in two parallel therapeutic directions — regenerative medicine and pain neuroscience — rather than focusing narrowly, which may reflect a platform technology (gene delivery, viral vectors, or cell engineering) applicable across multiple disease areas. Without post-2017 project entries, it is unclear whether they deepened either direction or pivoted after these collaborations ended.

With no H2020 projects after 2017 and a short two-project footprint, the company may have shifted focus toward commercial development or clinical-stage work rather than continued EU research network participation — worth verifying against their current pipeline before approaching for a consortium.

How they like to work

NSGENE has not led any H2020 project as coordinator, joining exclusively as a partner or participant — a pattern typical of SMEs that contribute niche expertise rather than administrative leadership. Both engagements were in large MSCA training consortia, where industry partners co-supervise researchers alongside universities. With 25 distinct partners across 10 countries, they have broad exposure to European academic networks despite a small project portfolio.

NSGENE has worked with 25 unique partners across 10 countries, a notably wide network for an organisation with only two projects — reflecting the large consortium structure typical of MSCA-ITN networks. Their connections are likely concentrated in Nordic, German, and UK life-science research institutions given the nature of these networks.

What sets them apart

NSGENE occupies a rare position as a Danish private-sector SME inside MSCA training networks, giving it direct relationships with academic research groups across Europe that most companies of its size lack. Its focus on gene and cell-based approaches for neurological conditions is a commercially valuable niche, particularly as gene therapy moves toward clinical and market stages. For consortium builders, NSGENE adds the credibility of an industry end-user or exploitation partner to academic-heavy teams.

Highlights from their portfolio

• Training4CRM
  A flagship MSCA European Training Network in cell-based regenerative medicine spanning 2016–2020, where NSGENE's industry participation gave doctoral researchers direct exposure to commercial gene/cell therapy development.
• PAIN-Net
  A molecule-to-man pain network running 2017–2021 that signals translational ambition — bridging basic pain science with clinical or commercial applications — and broadens NSGENE's profile beyond pure regenerative medicine.